Cannabis effects on cardiovascular health: Current evidence, gaps in knowledge, and future research directions.
Cannabis effects on cardiovascular health: Current evidence, gaps in knowledge, and future research directions.
Narrative review finds mixed cardiovascular evidence for cannabis use, with strongest association for atrial arrhythmias but significant knowledge gaps remaining.
This comprehensive review demonstrates that cardiovascular safety signals from cannabis use are inconsistent across most outcomes, with many associations weakening after statistical adjustment for confounding variables. The exception is atrial arrhythmias, where evidence appears more robust and consistent across studies.
With cannabis legalization expanding globally and high-potency products becoming more available, clinicians need clear guidance on cardiovascular risks for patient counseling. This review highlights that definitive safety conclusions remain elusive for most cardiovascular endpoints.
| Study Type | Narrative Review |
| Population | Human participants from peer-reviewed studies published 2014-2025 |
| Intervention | Cannabis use (primarily THC-containing formulations) |
| Comparator | Non-users or control groups from included studies |
| Primary Outcome | Cardiovascular outcomes including myocardial infarction, stroke, MACE, and arrhythmias |
| Key Finding | Mixed associations for major cardiovascular events, stronger consistent association for atrial arrhythmias |
| Journal | Trends in Cardiovascular Medicine |
| Year | 2025 |
Current evidence does not support definitive cardiovascular contraindications for cannabis use in most patients, but atrial arrhythmia risk appears more substantiated. Clinicians should exercise heightened caution in patients with existing arrhythmia disorders or risk factors.
As a narrative review without systematic methodology, this paper cannot provide quantitative risk estimates or definitive causal relationships. The review acknowledges significant knowledge gaps and does not establish clear dose-response relationships or comparative safety profiles across different cannabis formulations.
Narrative reviews lack the systematic rigor of meta-analyses and may be subject to selection bias in study inclusion. The heterogeneity of cannabis products, dosing, and study populations makes synthesis challenging, and residual confounding likely persists in observational data.
The cardiovascular safety profile of cannabis remains incompletely defined, requiring individualized risk assessment rather than categorical recommendations. Atrial arrhythmia risk deserves particular attention in susceptible patients, while evidence for other major cardiovascular events remains mixed and confounded.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What cardiovascular risks should I discuss with patients who use cannabis?
Current evidence shows the strongest and most consistent association between THC use and atrial arrhythmias. While observational studies suggest mixed associations with myocardial infarction, stroke, and major adverse cardiovascular events, many findings are attenuated after adjusting for confounding factors.
Is cannabis use safe for patients with existing heart conditions?
The evidence remains unclear and inconsistent regarding cardiovascular safety in patients with pre-existing conditions. Given the stronger association with atrial arrhythmias and potential for other cardiovascular effects, patients with existing heart disease should be counseled about these risks and monitored closely.
Does the potency or type of cannabis product affect cardiovascular risk?
High-potency THC formulations are of particular concern as cannabis legalization has led to increased availability of these products. However, specific dose-response relationships and comparative risks between different cannabis formulations require further research to establish clear clinical guidance.
What should I tell patients about cannabis and blood clot risk?
The evidence for venous thromboembolism risk associated with cannabis use appears limited based on current research. However, given the mixed and evolving evidence base, patients should be informed that cardiovascular risks, including potential thrombotic events, cannot be ruled out.
How should I monitor patients who continue cannabis use despite cardiovascular concerns?
Focus monitoring on cardiac rhythm abnormalities given the strongest evidence for atrial arrhythmias with cannabis use. Regular cardiovascular assessments and patient education about symptoms of arrhythmias, chest pain, or other cardiovascular events are important given the significant knowledge gaps in current evidence.
